Pages that link to "Q46966725"
Jump to navigation
Jump to search
The following pages link to Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects (Q46966725):
Displaying 13 items.
- Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage (Q34023636) (← links)
- Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure (Q34502676) (← links)
- Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM (Q35932449) (← links)
- Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions (Q36261125) (← links)
- Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. (Q36920649) (← links)
- Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? (Q37107490) (← links)
- Antioxidant supplemention in the treatment of skeletal muscle insulin resistance: potential mechanisms and clinical relevance (Q37112535) (← links)
- Skeletal Muscle Vascular Function: A Counterbalance of Insulin Action. (Q38436848) (← links)
- Evaluation of rosiglitazone administration on cardiovascular function in severe obesity (Q46195003) (← links)
- Confusion over thiazolidinedione-induced heart failure: need for a better definition of heart failure (Q46569270) (← links)
- Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes (Q46973474) (← links)
- Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients (Q51474253) (← links)
- Preserved response to diuretics in rosiglitazone-treated subjects with insulin resistance: a randomized double-blind placebo-controlled crossover study (Q83517537) (← links)